Benjamin M. Weide
Expertise in
1
conditions

Benjamin M. Weide

Tuebingen, BW, DE 
Expertise in
1
conditions
Tuebingen, BW, DE 

Overview

Benjamin Weide practices practicing medicine in Tuebingen, Germany.

Mr. Weide is highly rated in 1 condition, according to our data. His clinical expertise encompasses Melanoma, Anal Cancer, Neuroendocrine Tumor, and Brain Tumor.

He is actively involved in clinical research, co-authoring 104 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Tuebingen, BW, Germany
Other Locations
Stuttgart, BW, Germany
Tubingen, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Vemurafenib, Cobimetinib, Atezolizumab
Study Phase: Phase 2
A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients
A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Procedure, Drug
Study Drugs: L19IL2, L19TNF
Study Phase: Phase 3
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation
Enrollment Status: Completed
Publish Date: June 07, 2024
Intervention Type: Drug
Study Drugs: LGX818, MEK162, Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma
Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma
Enrollment Status: Unknown
Publish Date: November 04, 2021
Intervention Type: Biological
Study Drugs: CV8102, Anti-PD-1 Therapy
Study Phase: Phase 1
View 3 Less Clinical Trials

104 Total Publications

Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.
Journal: Journal for immunotherapy of cancer
Published: December 04, 2025

Frequently Asked Questions about Benjamin M. Weide

Is Benjamin M. Weide a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Benjamin M. Weide is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Benjamin M. Weide participate in research or clinical trials?

Yes. Benjamin M. Weide has published 104 articles and abstracts on conditions like Melanoma. You can view a list of Benjamin M. Weide's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Weide's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile